The evidence base for Hormone Replacement Therapy (HRT): what can we believe?

The'facts'that most women and clinicians consider in making the decision to use, or not use, HRT are frequently wrong or incorrectly applied according to a professor. New research raises serious questions about the'facts'that have led women and their doctors to believe hormone therapy (often called HRT) is unsafe.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Hormone replacement therapy has been shown to be effective in alleviating menopausal symptoms. However, its use is controversial owing to potential health risks, such as thromboembolism and cancer. Bioidentical hormone therapy has recently become popular as an alternative to conventional hormone replacement therapy. These bioidentical hormones have a molecular structure identical to endogenous hormones found in a woman's body. A claimed advantage of bioidentical hormone therapy is the compounding practice in order to individualize therapy depending on patient's own hormone levels and symptoms. However, there is no scientif...
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
Abstract Hormone replacement therapy has been shown to be effective in alleviating menopausal symptoms. However, its use is controversial owing to potential health risks, such as thromboembolism and cancer. Bioidentical hormone therapy has recently become popular as an alternative to conventional hormone replacement therapy. These bioidentical hormones have a molecular structure identical to endogenous hormones found in a woman's body. A claimed advantage of bioidentical hormone therapy is the compounding practice in order to individualize therapy depending on patient's own hormone levels and symptoms. However, th...
Source: Dermatol Online J - Category: Dermatology Authors: Tags: Dermatol Online J Source Type: research
Conclusions and Relevance Transgender patients are more likely to be engaged and seek care if their identity and their needs are understood. While many aspects of transgender health care follow standard practices, there are significant and important differences, including gender-affirming therapies. This article aims to give gynecologists the necessary tools to partner in the care of transgender patients. Target Audience Obstetricians and gynecologists, family physicians. Learning Objectives After participating in this activity, physicians should be better able to define “transgender”; distinguish healt...
Source: Obstetrical and Gynecological Survey - Category: OBGYN Tags: CME ARTICLES Source Type: research
Objective: Oxidized low-density lipoprotein (LDL) seems to play an important role in the etiology of atherosclerosis. To further study this, we performed two studies: (1) we determined the ability of 10 estrogen components of the drug, conjugated equine estrogen (CEE), trans-resveratrol (t-resveratrol) and quercetin (red wine components), trolox (vitamin E analog), and probucol (a serum cholesterol-lowering drug) to delay or prevent the oxidation of plasma LDL isolated from untreated postmenopausal women, and (2) we assessed the effect of long-term (>1 year) estrogen replacement therapy and hormone replacement therapy...
Source: Menopause - Category: OBGYN Tags: Commemorative Papers Source Type: research
18 October 2018   is World Menopause Day and October is World Menopause Month.Cochrane Gynaecology and Fertility Group has published multiple reviews assessing the effectiveness and safety of interventions in menopausal women, including peri and postmenopausal women. To celebrate World Menopause Day we have collated a special selection of reviews investigating various treatments  for menopausal symptoms such as hormone therapy, tibolone, relaxation, exercise, and alternative therapy.Black cohosh (Cimicifuga spp.) for menopausal symptomsDehydroepiandrosterone for women in the peri- or postmenopausal phaseHormone t...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news
Our panel this morning discussed the issues surrounding how the WHI results were interpreted and communicated to women and their health care providers. We recognize that hormones are not appropriate for all women, and look forward to hosting a future panel that highlights alternatives. The speakers have a variety of backgrounds and experiences (and genders), and we aim to promote diversity of voices. This was not normal breakfast conversation. Today was a jolting – and disruptive – talk about what happens to women’s bodies when they age. (Who knew that if you’re menopausal and you don’t take y...
Source: Disruptive Women in Health Care - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: blogs
THIS WEEK'S TOP STORIES Hormone therapy: Is it right for you??? Hormone replacement therapy ? medications containing female hormones to replace the ones the body no longer makes after menopause ? is sometimes used to treat common menopausal symptoms, including hot flashes and vaginal discomfort. Hormone therapy also has been proven to prevent bone loss [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news
CONCLUSIONS: Biallelic mutations in POLG may be associated with ovarian dysfunction. This study has improved our understanding of POLG-related genetic mutations in ovarian dysfunction, and the mode of inheritance of certain sequence variants. This information will assist genetic counseling and precision medicine in the future. PMID: 29992832 [PubMed - as supplied by publisher]
Source: Climacteric - Category: Geriatrics Authors: Tags: Climacteric Source Type: research
ConclusionsAsian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were significantly associated with the risk of all breast cancer histological types and ER-positive breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Currently, there is insufficient high-quality evidence to inform women considering HRT after treatment for endometrial cancer. The available evidence (both the single RCT and non-randomised evidence) does not suggest significant harm, if HRT is used after surgical treatment for early-stage endometrial cancer. There is no information available regarding use of HRT in higher-stage endometrial cancer (FIGO stage II and above). The use of HRT after endometrial cancer treatment should be individualised, taking account of the woman's symptoms and preferences, and the uncertainty of evidence for and against HRT use. ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
More News: Hormonal Therapy | Hormone Replacement Therapy | Hormones | Science | Women